Heart failure is the final stage of various cardiovascular diseases.Cardiac stimulant,diuretic,vasodilators com-bined with sympathetic nerve inhibition and renin-angiotensin-aldosterone system inhibition are the means of clinical heart failure treating.To a certain extent,they delay the progression of heart failure.But the recurrence rate and mortality of heart failure patients are still very high.In recent years,with the widespread use of the diabetes drug-dapagliflozin,we have found that it can benefit patients with heart failure.Dapagliflozin was approved for the treatment of heart failure in February 2021 and has been widely used in clinical practice.A review of the latest research progress of the sodium glucose cotransporter-2 inhibitor dapagliflozin in the field of heart failure is presented.
国家科技期刊平台
NSTL
万方数据
